Referrals can be an absolute game-changer in recruitment.When someone in your network recommends a candidate, they often have firsthand insight into the person’s skills, work ethic, values and ambitions. This insider knowledge results in higher quality candidates who are a…
HOME > ACADEMIA
ACADEMIA
- JSH’s Committee Calls for Guidelines to Clarify Relations Between Companies, Research Institutions
June 3, 2014
- VART Study Lead Investigator to Discuss with Co-Authors, Mull Paper Retractions
May 28, 2014
- Eisai Responds to Media Report of Allegations of Data Falsification in J-ADNI Study
May 28, 2014
- Chiba Univ. Advises Authors to Withdraw VART Papers
May 26, 2014
- Sapporo Hospital Sorry for Ethical Guidelines Violations in Nesp Clinical Study
May 19, 2014
- Chiba University Hospital Suspends Use of Novartis’s Products in Response to Scandal over VART Study
May 12, 2014
- Careful Approach Needed in Legislating for Clinical Research: JAMS Pres.
May 8, 2014
- VART Lead Investigator “Wants to Seriously Take University Advice” on Retracting Diovan Papers
May 2, 2014
- Claims of Superior Cardiorenal Protective Effects of Diovan “Cannot Be Supported”: Outside Investigation of VART Study
April 30, 2014
- Chiba University to Advise Researchers to Retract Diovan Papers
April 28, 2014
- US Journal Corrects COI Disclosure to Clarify Involvement of Shionogi and Eli Lilly Japan in Paper on “Pain in Depression”
April 23, 2014
- JSBMR’s Guidelines Recommend Alendronate, Risedronate as First-Line Therapies for Steroid-Induced Osteoporosis Based on Available Data
April 22, 2014
- Public Hospitals Seeking to Avert Penalty Fee Cuts for Low Price Settlements
April 14, 2014
- JSH Publishes New Hypertension Guidelines
April 3, 2014
- Tolvaptan Reduces Body Weight, Improves Congestive Symptoms; Adverse Reactions Seen in Less than 20% of Patients: Interim Analysis of PMS Data
March 26, 2014
- Edoxaban Subgroup Analysis of East Asian Patients “Consistent” with Global Study Results: Researcher
March 25, 2014
- Revised Treatment Guidelines for HER2-Positive Gastric Cancer Will Recommend Combination Therapy with Trastuzumab
March 25, 2014
- Current Tax Rules for Medical Fees Unreasonable, Litigation an Option: Major Hospital Chain
March 25, 2014
- Experts Disagree over Full-Introduction of GCP at JCS Meeting
March 24, 2014
- NCNP Research Group Confirms Efficacy of Tocilizumab for Neuromyelitis Optica
March 19, 2014
ページ
Chugai Pharmaceutical’s Phesgo (pertuzumab + trastuzumab + vorhyaluronidase alfa) and Novartis’ Leqvio (inclisiran) will be newly added to the Japanese reimbursement list along with a batch of other medicines on November 22. Three drugs carry peak sales outlooks of over…
The main players in the FY2024 reimbursement policy reform are now all in place, with the roster rounded out by the appointment of former health minister Katsunobu Kato for the Liberal Democratic Party’s (LDP) prominent social security post at the…
A member of the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry on November 13…
Many members of a key reimbursement policy panel on November 10 called on the health ministry to revisit the current listing requirement of at least 25 years for the designation of essential medicines now that annual revisions have been introduced…
A health ministry study group on pharmaceutical regulations on October 13 roughly agreed on a reform plan for Japanese regulatory…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…